8 completed, 5 withdrawn. 8 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Withdrawn 5, Completed 3 |
| Phase 1 | 5 | Completed 5 |
Follow RNS60: new trials by email Literature Review of RNS60 trials Research Report on RNS60
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis RNS60, Placebo - Amyotrophic Lateral Sclerosis | Phase 2 | Withdrawn | Revalesio Corporation | 2026-10-01 | 2026-04-16 | |
| Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy RNS60, Placebo - Stroke, Ischemic | Phase 2 | Completed | Revalesio Corporation | 83 | 2021-07-07 | 2026-01-12 |
| The Effect of RNS60 on ALS Biomarkers RNS60 - Amyotrophic Lateral Sclerosis | Phase 2 | Completed | Mario Negri Institute for Pharmacological Research | 147 | 2017-05-30 | 2023-04-21 |
| A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS) RNS60 - ALS | Phase 1 | Completed | Sabrina Paganoni, M.D. | 24 | 2015-10-01 | 2021-05-28 |
| Systemic Bioactivity of Inhaled Nebulized RNS60 RNS60, Normal saline - Systemic Bioactivity of Nebulized RNS60 | Phase 1 | Completed | Revalesio Corporation | 56 | 2015-07-01 | 2015-09-22 |
| Effect of RNS60 on the Late Phase Asthmatic Response to Allergen Challenge RNS60, Placebo - Asthma | Phase 2 | Completed | Revalesio Corporation | 30 | 2015-04-01 | 2016-12-09 |
| Study of Inhaled RNS60 in Combination With Budesonide to Treat Mild to Moderate Asthma RNS60, Normal Saline, Budesonide - Asthma | Phase 1 | Completed | Revalesio Corporation | 65 | 2012-06-01 | 2014-07-28 |
| Safety and Tolerability of RNS60 Given by IV to Healthy Subjects RNS60, Placebo - Myocardial Infarct | Phase 1 | Completed | Revalesio Corporation | 12 | 2011-07-01 | 2011-10-04 |
| Safety Study of Nebulized RNS60 to Treat Asthma. RNS60, RNS60 - single dose - Asthma | Phase 1 | Completed | Revalesio Corporation | 36 | 2010-05-01 | 2012-01-12 |
| Study of RNS60 on Pain and Function After Knee Anterior Cruciate Ligament Surgery RNS60 - Anterior Cruciate Ligament Reconstruction | Phase 2 | Withdrawn | Revalesio Corporation | 2015-04-10 | ||
| Pilot Study of RNS60 in Allergen-induced Bronchoconstriction RNS60, Normal Saline - Asthma | Phase 2 | Withdrawn | Revalesio Corporation | 2016-10-04 | ||
| Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis RNS60 125 ml, RNS60 250 ml, Interferon beta 1a - Relapsing Remitting Multiple Sclerosis | Phase 2 | Withdrawn | Revalesio Corporation | 2016-04-06 | ||
| Study of RNS60 on Pain and Function After Hip Labral Repair RNS60, Saline - Hip Labral Tear | Phase 2 | Withdrawn | Revalesio Corporation | 2015-02-06 |
Asthma (4) · Amyotrophic Lateral Sclerosis (2) · Ischemic Stroke (1) · Multiple Sclerosis, Relapsing-Remitting (1) · Myocardial Infarction (1)
Revalesio Corporation (11) · Mario Negri Institute for Pharmacological Research (1) · Sabrina Paganoni, M.D. (1)
United States (9) · United Kingdom (2) · Italy (1)
Ettore Beghi, MD (1) · Fred Lublin, MD, PhD (1) · Kari C Nadeau, M.D., Ph.D. (1) · Kelly Craven, M.D. (1) · Nazem Atassi, MD (1) · Richard L Watson, M.D. (1) · Sabrina Paganoni, MD (1)